On the basis of therapy, the China paroxysmal nocturnal hemoglobinuria (PNH) therapeutics market can be segmented into medication therapy, stem cell therapy and blood transfusion therapy.
Medication therapy includes Eculizumab (Soliris), Pegcetacoplan, Ravulizumab. The mainstay of PNH treatment is the drug Eculizumab (Soliris). It is a humanized monoclonal antibody that binds to proteins in the blood that can destroy red blood cells. The drug reduces the risk of thrombosis and can improve quality of life in PNH patients.
Stem cell therapy may be appropriate for patients who do not respond to Eculizumab or for those who have severe reductions in red blood cells, white blood cells and platelets.
By Diagnosis Test:
On the basis of diagnostic tests, the China paroxysmal nocturnal hemoglobinuria (PNH) therapeutics market can be divided into complete blood count test (CBC), lactate dehydrogenase test (LDH), bilirubin test, bone marrow examination, urine test for hemosiderin and flow cytometry.
Currently, diagnosis of PNH is with flow cytometry, which is used to determine the absence of specific RBC or white blood cell cell surface proteins (CD59 and CD55). This test is highly sensitive and specific. Flow cytometry has become the gold standard for making the diagnosis.
Bone marrow examination is indicated when bone marrow transplantation is being considered and to rule out other disorders when pancytopenia is present. Cytogenetic analysis of bone marrow samples is recommended to help identify underlying disease processes associated with PNH.
By Distribution Channel:
On the basis of distribution channel, the China paroxysmal nocturnal hemoglobinuria (PNH) therapeutics market can be segmented into retail, online and hospital pharmacies. During the forecast period (2019-2028) hospital pharmacies is the key distribution channel segment of the paroxysmal nocturnal hemoglobinuria (PNH) therapeutics market. Growth of the hospital pharmacies segment can be attributed to increasing incidence of paroxysmal nocturnal hemoglobinuria (PNH) and rising number of admissions of patients with the disease. Clinical examination and supporting laboratory investigations for the diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) are best possible in hospitals.
Some of the key players in China Paroxysmal Nocturnal Hemoglobinuria (PNH) therapeutics market are Alexion Pharmaceuticals, Inc; Samsung Bioepis Co. Ltd; AffaMed Therapeutics; Amgen Inc; Novartis AG; CANbridge Pharmaceuticals, Inc.
Key players are adopting various strategies such as licensing agreement, collaboration and partnerships. For instance, Samsung Bioepis Co. Ltd. entered in China by licensing agreement with C-Bridge Capital.
Samsung Bioepis Co. Ltd. and AffaMed Therapeutics announced that the China National Medical Products Administration (NMPA) has approved the Clinical Trial Application (CTA) for SB12, also referred to as AMT904 in China – a biosimilar candidate referencing Soliris (eculizumab). SB12 (also referred to as AMT904) is an eculizumab biosimilar candidate for the treatment of paroxysmal nocturnal hemoglobinuria.
Iptacopan- Pipeline drug of Novartis for paroxysmal nocturnal hemoglobinuria.
CANbridge is developing CAN106 in conjunction with WuXi Biologics for treatment of paroxysmal nocturnal hemoglobinuria.